Join Growin Stock Community!

Opko health, inc.OPK.US Overview

US StockHealthcare
(No presentation for OPK)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

OPK AI Insights

OPK Overall Performance

OPK AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

OPK Recent Performance

-1.67%

Opko health, inc.

0.05%

Avg of Sector

-0.31%

S&P500

OPK PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

OPK Key Information

OPK Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

OPK Profile

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins. The company also offers specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. In addition, it operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.

Price of OPK

OPK FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

OPK Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.29
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1.57
PB Ratio
0.69
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
33.93%
Net Margin
-37.19%
Revenue Growth (YoY)
-14.90%
Profit Growth (YoY)
-5.75%
3-Year Revenue Growth
-7.13%
3-Year Profit Growth
4.57%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.29
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1.57
PB Ratio
0.69
Price-to-FCF
-
Gross Margin
33.93%
Net Margin
-37.19%
Revenue Growth (YoY)
-14.90%
Profit Growth (YoY)
-5.75%
3-Year Revenue Growth
-7.13%
3-Year Profit Growth
4.57%

  • When is OPK's latest earnings report released?

    The most recent financial report for Opko health, inc. (OPK) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating OPK's short-term business performance and financial health. For the latest updates on OPK's earnings releases, visit this page regularly.

  • What is the operating profit of OPK?

    According to the latest financial report, Opko health, inc. (OPK) reported an Operating Profit of -38.32M with an Operating Margin of -25.81% this period, representing a decline of 15.63% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is OPK's revenue growth?

    In the latest financial report, Opko health, inc. (OPK) announced revenue of 148.45M, with a Year-Over-Year growth rate of -19.16%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does OPK have?

    As of the end of the reporting period, Opko health, inc. (OPK) had total debt of 389.44M, with a debt ratio of 0.2. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does OPK have?

    At the end of the period, Opko health, inc. (OPK) held Total Cash and Cash Equivalents of 369.07M, accounting for 0.19 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does OPK go with three margins increasing?

    In the latest report, Opko health, inc. (OPK) did not achieve the “three margins increasing” benchmark, with a gross margin of 43.1%%, operating margin of -25.81%%, and net margin of -21.1%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess OPK's profit trajectory and future growth potential.

  • Is OPK's EPS continuing to grow?

    According to the past four quarterly reports, Opko health, inc. (OPK)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.04. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of OPK?

    Opko health, inc. (OPK)'s Free Cash Flow (FCF) for the period is -28.49M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 42.72% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of OPK?

    The latest valuation data shows Opko health, inc. (OPK) has a Price-To-Earnings (PE) ratio of -4.08 and a Price/Earnings-To-Growth (PEG) ratio of 0.03. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.